These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7082548)

  • 1. The second peak in the serum levels curve after oral administration of a slow-release quinidine dosage form: effect of food.
    Spénard J; Sirois G; Gagnon MA
    Br J Clin Pharmacol; 1982 May; 13(5):752-5. PubMed ID: 7082548
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent.
    Regårdh CG; Johnsson G; Lundborg P; Perrson BA
    Arzneimittelforschung; 1977; 27(9):1716-8. PubMed ID: 21671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum quinidine levels after administration of three different quinidine preparations.
    Henning R; Nyberg G
    Eur J Clin Pharmacol; 1973 Dec; 6(4):239-44. PubMed ID: 4591150
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of quinidine Lipettes -- a sustained release preparation.
    Eriksson JE; Hanson A; Hörlin R; Johansson BW; Ohlsson O; Otto U; Syrén G
    Acta Med Scand; 1979; 205(1-2):53-9. PubMed ID: 367087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution.
    Sawyer WT; Pulliam CC; Mattocks A; Foster J; Hadzija BW; Rosenthal HM
    Biopharm Drug Dispos; 1982; 3(4):301-10. PubMed ID: 7159686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Blood level studies on the most suitable dosage forms in long-term quinidine therapy].
    Zettner H; Michel D
    Klin Wochenschr; 1971 May; 49(10):575-8. PubMed ID: 5578964
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum quinidine levels after chronic administration of four different quinidine formulations.
    Soeterboek AM; Van Thiel M; Eng C
    J Int Med Res; 1976; 4(6):393-401. PubMed ID: 1027633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Average steady-state plasma levels with slow release quinidine preparations].
    Normand JP; Roux A; Bardet J; Kahn JC; Maspoli JJ; Jarreau FX; Sansarricq M; Flouvat B; Bourdarias JP
    Arch Mal Coeur Vaiss; 1979 Sep; 72(9):1006-13. PubMed ID: 116611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinidine dosage, with special reference to an oral loading dose schedule.
    Collste P; Nordlander R
    Br J Clin Pharmacol; 1979 Mar; 7(3):293-7. PubMed ID: 427006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.
    Frigo GM; Perucca E; Teggia-Droghi M; Gatti G; Mussini A; Salerno J
    Br J Clin Pharmacol; 1977 Aug; 4(4):449-54. PubMed ID: 901736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid elimination of quinidine in pediatric patients.
    Szefler SJ; Pieroni DR; Gingell RL; Shen DD
    Pediatrics; 1982 Sep; 70(3):370-5. PubMed ID: 7110810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)].
    Knapp W; Lechleitner P
    Arzneimittelforschung; 1981; 31(9):1482-6. PubMed ID: 7197960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Blood levels of dihydroquinidine in man following oral administration of a delayed-action preparation].
    Maccari M; Lapeyre D; Maggi GC
    Farmaco Prat; 1979 Feb; 34(2):49-57. PubMed ID: 456541
    [No Abstract]   [Full Text] [Related]  

  • 14. [Study of blood quinidine levels obtained by the administration of delayed-action quinidine].
    Renais J; Scebat L; Lenègre J
    Arch Mal Coeur Vaiss; 1971 May; 64(5):701-11. PubMed ID: 4998224
    [No Abstract]   [Full Text] [Related]  

  • 15. Bioequivalence of quinidine in two sustained-release preparations.
    Garty M; Rachmel A; Ilfeld D; Sinai Y; Paz R
    Isr J Med Sci; 1992 Jun; 28(6):357-61. PubMed ID: 1607272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of food on the comparative bioavailability of a fast- and slow-release dosage form of quinidine gluconate.
    Spénard J; Sirois G; Gagnon MA
    Int J Clin Pharmacol Ther Toxicol; 1983 Jan; 21(1):1-9. PubMed ID: 6832862
    [No Abstract]   [Full Text] [Related]  

  • 17. Absolute bioavailability of quinidine in two sustained release preparations.
    Amlie JP; Storstein L; Olsson B; Fremstad D; Jacobsen S
    Eur J Clin Pharmacol; 1979 Aug; 16(1):45-8. PubMed ID: 499299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative quinidine plasma profiles at steady state of two controlled-release products and quinidine sulfate in solution.
    Wright GJ; Melikian AP; Pitts JE; Crowe JT; Morley EM
    Biopharm Drug Dispos; 1987; 8(2):159-72. PubMed ID: 3593896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Plasma level studies of quinidine retard, their significance for dosage and onset of effect].
    Guckenbiehl W; Just H; Olbermann M; Lang KF
    Med Klin; 1976 Apr; 71(14):586-92. PubMed ID: 57566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative multiple dose pharmacokinetics of quinine, quinidine and quinidine sustained release.
    Jamaludin A; Mohamad M; Navaratnam V; Mohamed N; Yeoh PY; Wernsdorfer WH
    Acta Leiden; 1989; 58(2):129-40. PubMed ID: 2489392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.